SPONSOR
Anhui Provincial Hospital
Total Trials
11
Recruiting
11
Phases
Phase 3, Phase 2, Phase 1
Conditions studied: Acute Graft Versus Host DiseaseSteroid-refractory Acute Graft-versus-host Disease(SR-aGVHD)Lymphoblastic LeukemiaRelapsed or Refractory Multiple Myeloma (RRMM)Esophageal Squamous Cell CarcinomaImmune Thrombocytopenia (ITP)Chemotherapy-induced NeutropeniaThrombocytopeniaLung CancerEsophageal Cancer
Anhui Provincial Hospital is a clinical research sponsor with 11 registered studies on ClinicalTrials.gov, of which 11 are actively recruiting participants. Research covers conditions including Acute Graft Versus Host Disease, Steroid-refractory Acute Graft-versus-host Disease(SR-aGVHD), Lymphoblastic Leukemia, Relapsed or Refractory Multiple Myeloma (RRMM).
The trial portfolio spans Phase 3, Phase 2, Phase 1 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Anhui Provincial Hospital
How many clinical trials has Anhui Provincial Hospital sponsored?
ClinicalMetric currently tracks 11 clinical trials sponsored by Anhui Provincial Hospital, of which 11 are actively recruiting participants. These trials cover conditions including Acute Graft Versus Host Disease, Steroid-refractory Acute Graft-versus-host Disease(SR-aGVHD), Lymphoblastic Leukemia. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Anhui Provincial Hospital research focus on?
Anhui Provincial Hospital clinical trials span Acute Graft Versus Host Disease, Steroid-refractory Acute Graft-versus-host Disease(SR-aGVHD), Lymphoblastic Leukemia, Relapsed or Refractory Multiple Myeloma (RRMM), Esophageal Squamous Cell Carcinoma, and additional conditions. The research pipeline includes Phase 3, Phase 2, Phase 1 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Anhui Provincial Hospital clinical trial?
To participate in a Anhui Provincial Hospital trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Anhui Provincial Hospital trials with current recruitment status updated daily.
Clinical Trials by Anhui Provincial Hospital
NCT07047456 Phase 3
Recruiting
Effect of Stem Cell Infusion Time on aGVHD in Patients With Hematological Malignancies Post UCBT
Acute Graft Versus Host Disease
NCT06321198
Recruiting
A Trial to Evaluate the Safety and Preliminary Efficacy of iMesenchymal Stromal Cells(iMSC) in Subjects With SR-aGVHD
Steroid-refractory Acute Graft-versus-host Disease(SR-aGVHD)
NCT06961669
Recruiting
Intravenous Autologous CD19 CAR-T Cells for R/ R MM, B-ALL, and B-Cell Lymphoma
Lymphoblastic Leukemia
NCT06602843
Recruiting
Neoadjuvant Chemoimmunotherapy Followed by Surgery and Postoperative Radioimmunotherapy
Esophageal Squamous Cell Carcinoma
NCT06973356
Recruiting
Anti CD19/BCMA CAR Gene Therapy for Relapsed/Refractory Immune Thrombocytopenia
Immune Thrombocytopenia (ITP)
NCT06408584
Recruiting
Short-course Hypofractionated Radiotherapy in Combination With Raltitrexed and Tislelizumab
Esophageal Squamous Cell Carcinoma
NCT07096479
Recruiting
Telpegfilgrastim Injection to Reduce the Risk of Neutropenia in Patients With Solid Tumor
Chemotherapy-induced Neutropenia
NCT06673498 Phase 2
Recruiting
Lusutrombopag Combined With Recombinant Human Thrombopoietin for the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Destined to Undergo Elective Invasive Surgery
Thrombocytopenia
NCT06232083 Phase 1
Recruiting
A Multi Tumor, Open Phase I Clinical Study on the Progression of First-line Anti-tumor Therapy Using Cardonizumab Combined With Pulsed Low-dose Rate External Irradiation (PLDR)
Lung Cancer
NCT06664021 Phase 2
Recruiting
Exploring the Efficacy and Safety of Tislelizumab in Combination With S-1 in the Treatment of Patients With Postoperative Recurrent High-risk Intrahepatic Cholangiocarcinoma
Intrahepatic Cholangiocarcinoma
NCT06362967 Phase 2
Recruiting
The Efficacy and Safety of Desensitation Regimen for Patients With High Titers of Anti-HLA Antibodies Prior to Allo-HSCT
High Titers of Anti-HLA Antibody (MFI ≥5000)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: November 2026 · Data Methodology